Matthew Roden, PhD, is Head of Strategic Corporate Development, and Global Business Development Assessment at Bristol-Myers Squibb, where he oversees the Mergers & Acquisition (M&A) and Search and Evaluation (S&E) teams. In this role, Matt works with leaders across the organization to recommend creative options and proactive strategies to expand the R&D and product portfolios. Prior to joining BMS, Matt was Head of Biotechnology Equity Research at UBS, covering the technical, strategic, and financial outlook for biotech companies regardless of therapeutic area. Prior to joining UBS in 2010, he was a Senior Analyst covering biotechnology at J.P. Morgan, Bank of America Merrill Lynch, and launched his Wall Street career as an Associate at Credit Suisse First Boston. Matt holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, and earlier was a pre-doctoral clinical research fellow in immuno-oncology at the National Cancer Institute in Bethesda, MD.